MDR-001 (GLP-1 agonist)
Phase 3 registry
Since , the date of the source that reports this phase.
Summary
MDR-001 is a GLP-1 agonist from MindRank. The source describes it as small molecule. It is being developed for overweight or obesity. ClinicalTrials.gov lists it at Phase 3 (not yet recruiting) under NCT07274137, NCT06778850. The AI role named in the source is molecule design. Registry records: NCT07274137, Phase 3, not yet recruiting, updated Dec 22, 2025; NCT06778850, Phase 1/2, completed, updated Sep 18, 2026. The Phase 3 trial record (NCT07274137) is still not yet recruiting. The latest dated source is from Feb 26, 2026.
Built only from the sources listed on this page.
Facts
- Company
- MindRank
- Indication
- Overweight or obesity
- Therapeutic area
- Metabolic
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Phase 3 (registered, not yet recruiting), as of Feb 26, 2026
- Phase source
- Registry
- Board column
- Phase 3
Key readouts in the source
The Phase 3 trial record (NCT07274137) is still not yet recruiting.
AI evidence
AI source: Company
“MDR-001 is a biased, selective oral GLP-1 receptor agonist discovered and optimized using MindRank’s proprietary AI-enabled drug discovery platform.”
Trial records
- NCT07274137 on ClinicalTrials.gov (opens in new tab) Phase 3 Not yet recruiting Updated
- NCT06778850 on ClinicalTrials.gov (opens in new tab) Phase 1/2 Completed Updated
Milestone timeline
-
NCT07274137 record updated
Phase 3, Not yet recruiting
-
ClinicalTrials.gov record: Phase 3 (registered, not yet recruiting)
The Phase 3 trial record (NCT07274137) is still not yet recruiting.
-
NCT06778850 record updated
Phase 1/2, Completed
-
Registry check
Phase 3 NCT07274137 still Not yet recruiting (last update 2025-12-22) though post says first patient dosed.
NCT07274137 (opens in new tab)NCT06778850 (opens in new tab)
Spot an error? Tell me and I'll fix it.